Sep 2026
FasL-mediated death of activated intratumoral T cells drives secondary resistance to cancer immunotherapy.
Cancer progression following an initial response to immunotherapy (secondary resistance; 2°R) is a major and poorly understood problem. We treated mice bearing B16 melanoma with a combination of a regulatory T cell (Treg) depleting, non-IL-2 blocking antibody (anti-CD25NIB) and an autologous cancer cell vaccine (GVAX)....
Chen Qing, E. Ghorani, K. Foster et al.
· Cancer immunology research · 0 citations